IQVIA (NYSE:IQV) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Truist Financial reiterated a “buy” rating and set a $265.00 target price (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. JPMorgan Chase & Co. upped their price target on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. BMO Capital Markets started coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective for the company. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Stifel Nicolaus increased their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $241.44.

IQVIA Stock Up 0.3%

NYSE:IQV opened at $225.68 on Friday. IQVIA has a 52 week low of $134.65 and a 52 week high of $234.29. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock’s fifty day moving average is $214.48 and its two-hundred day moving average is $186.71. The stock has a market capitalization of $38.43 billion, a price-to-earnings ratio of 30.96, a price-to-earnings-growth ratio of 2.53 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in IQV. Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after purchasing an additional 312,807 shares during the period. Alliancebernstein L.P. lifted its stake in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after buying an additional 41,643 shares during the last quarter. Boston Partners acquired a new stake in shares of IQVIA in the third quarter valued at approximately $676,698,000. Artisan Partners Limited Partnership grew its position in shares of IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after acquiring an additional 161,085 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.